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Infection after a primary total-joint replacement can be devastating. If the infecting organism is meth-
icillin resistant, the chance of successful eradication of the infection is considerably decreased. What is
more concerning is that these organisms are becoming increasingly common in periprosthetic joint
infection. We have reviewed the literature and have outlined the effectiveness of single- and two-stage
treatment regimens for this difﬁcult problem. We have also looked at the screening and decolonisation
methods that have been implemented in an attempt to decrease the risk of surgical site infections. Lastly,
we outline our recommendations on how we should tackle this emerging and difﬁcult problem that is
affecting the orthopaedic world.
中 文 摘 要
全關節置換術後的感染之破壞性極大。若果感染的細菌為抗甲氧西林時，成功根絕感染的機會是相當之低，
更使人擔心的是這類型的細菌在關節假體周圍的感染愈來愈普遍。對於這種難題，我們重新探討文獻並概述I
和II期翻修術的治療方案，也仔細檢查篩選法和去细菌定植法的實施，在減少手術處感染風險之效用。最
後，我們概述一些建議，應該怎樣去處理這些正在影響矯型骨科界新出現的難題。Introduction and Background
Infections after total-joint replacement have always posed
a difﬁcult problem for the treating orthopaedic surgeons and the
multidisciplinary team. Incidence rates of infection after primary
total-joint replacement have historically ranged between 1% and
2%, whereas for revision procedures, they range from 3% to 4%.1
When an infection occurs, the resulting costs can exceed three to
four times the cost of a primary total-joint replacement resulting in
a large ﬁnancial burden to both the patient and the health care
system.2 The most common offending organisms are typically
Staphylococcus species, namely, Staphylococcus aureus or Staphylo-
coccus epidermidis. Decades earlier, most of these organisms were
sensitive to ﬁrst-line antibiotics; however, more recently, there has
been an alarming trend of higher rates of methicillin-resistant
infective organisms causing periprosthetic infections.
Parvizi et al3 reported a steady increase in the prevalence
of infections caused by methicillin-resistant organisms, most
prominently Staphylococcus species. Methicillin-resistant S aureusa.
ngOrthopaedicAssociationandHongKo(MRSA) infections were noted to increase from 16% in 1999 to 37%
in 2006, and methicillin-resistant S epidermidis infections showed
a similar increase from 11% to 25% from 1999 to 2006. They also
noted that methicillin-resistant organisms became the most
dominant infecting organisms within the ﬁnal 3 years of the study,
with the incidence of methicillin-resistant cases outnumbering the
infections caused by methicillin-sensitive species. This trend is
indeed worrisome.
Many reasons have been advanced to explain this increase in
methicillin-resistant infections; themost common one is the liberal
use of antibiotics by the medical community as a whole for the past
half century. Other reasons include the increased use of invasive
haemodynamic monitoring devices and the rise in the number of
surviving immunocompromised patients secondary to advances in
modern medical technology. We are also seeing an increase in the
colonisation of methicillin-resistant organisms in the general
population as well as among physicians and health care workers.
In a recently published article by Schwarzkopf et al,4 the authors
examined the prevalence of the colonisation of methicillin-
sensitive and resistant S aureus species in the nares of ortho-
paedic surgeons and residents. They obtained nasal swabs from 74ngCollegeofOrthopaedic Surgeons. PublishedbyElsevier (Singapore) Pte Ltd.All rights reserved.
A.P. Van Houwelingen et al. / Journal of Orthopaedics, Trauma and Rehabilitation 16 (2012) 9e1210orthopaedic surgeons and 61 orthopaedic residents from a univer-
sity hospital in New York and compared the colonisation rates with
those of their patient population. They demonstrated similar
colonisation rates among the orthopaedic surgeons, residents, and
the high-risk patient population. The colonisation rates for
methicillin-sensitive S aureus (MSSA) were 23.3% across the
orthopaedic surgeons, 59.0% among the orthopaedic residents, and
18% in the sampled patient population. As for the colonisation rates
of MRSA, the results showed a 2.7% prevalence rate across the
orthopaedic surgeons, a similar 2.17% rate seen in the patient
population, and no MRSA colonisation among the sampled ortho-
paedic residents. This article demonstrates the relatively high
prevalence of carrier status of MSSA and MRSA among orthopaedic
surgeons and residents in a typical university hospital setting, thus
highlighting the importance of health care professionals to practise
proper hand hygiene and other precautionary measures to mini-
mise the risk of surgical site infection (SSI). In addition, this article
shows a gradual increase in colonisation in orthopaedic surgeons as
they progress from residency to practice, presumably because of
more frequent exposure to patients who are carriers.
Single-stage Treatment
Completely eradicating deep periprosthetic infections remains
a challenging problem faced by orthopaedic surgeons, especially in
the face of increasing rates of methicillin-resistant infections. In the
past, for acute periprosthetic total-joint infections, open irrigation
and debridement and component retention achieved a reliable rate
of infection eradication if the timing from the onset of infection to
surgerywaswithin theﬁrst fewweeks.5 However, these data largely
dealtwith infections caused bymethicillin-sensitive organisms. The
more recent literature suggests ahigher rate of failure using a single-
stage approach when dealing with methicillin-resistant organisms.
Bradbury et al6 looked at 19 cases of acute periprosthetic MRSA
total-knee infections managed by open debridement and compo-
nent retention with a minimum of 4 weeks of postoperative intra-
venous vancomycin therapy. At 2-year follow-up, 16 of the 19 cases
(84%) had failed and become reinfected, with 13 patients requiring
a subsequent two-stage exchange procedure. In amuch larger study,
Parvizi et al7 compared the effectiveness of open debridement and
component retentionwith that of two-stage exchange arthroplasty
in treating periprosthetic infection caused by methicillin-resistant
staphylococcal species. They reviewed 127 patients, of whom 35
underwent open debridement and retention of the prosthesis and
92 underwent a full two-stage component exchange. At aminimum
of 2 years’ follow-up, debridement alonewas successful in only 37%,
whereas two-stage exchange arthroplasty had success rates of 60%
for total knee replacement (TKA) and 75% for total hip replacement
(THA). These ﬁndings suggest that there may be evidence for a shift
in the treatment algorithm for acute periprosthetic total-joint
infections to favour immediate removal of the prosthesis and
subsequent two-stage component exchange when the offending
organism is found to be methicillin resistant or for only using
debridement and irrigation within the ﬁrst few days of symptom
onset as opposed to the ﬁrst few weeks.
Two-stage Treatment
Two-stage component exchange arthroplasty with intervening
culture-speciﬁc intravenous antibiotic-directed treatment remains
the gold standard for any type of periprosthetic joint infection. In
today’s landscape of increasing methicillin-resistant infections, it
remains the best treatment for affected patients. Even so, the failure
rate of this treatment strategy, as it applies to methicillin-speciﬁc
infections, is emerging as a signiﬁcant cause for concern.Table 17e13,15 outlines numerous two-stage component exchange
studies over the past 10 years that have demonstrated less-than-
optimal results for the treatment of methicillin-resistant organisms
compared with the historical results of infections caused by
sensitive organisms.
The experience at our institution is summarised in the ﬁnal row
of Table 1, Leung et al.9 We elect to use the PROSTALAC (DePuy,
Warsaw, IN, USA) articulated cement spacers for our periprosthetic
infections. We adhere to strict surgical procedure protocols and
postoperative monitoring. The ﬁrst stage consists of removal of
infected implants, hardware, and cement followed by meticulous
debridement of all the infected tissue. We send a minimum of three
specimens for culture and sensitivity evaluation. The operative ﬁeld
is then thoroughly irrigatedwith 3 L of normal saline. Inmost of our
cases, the exact antibiotic composition of the articulated spacer
consisted of a combination of a minimum of 1.5 g vancomycin and
3.6 g tobramycin. All patients receive intravenous antibiotic
therapy or a combination of intravenous and oral antibiotics for
a minimum of 6 weeks, under the supervision of an Infectious
Disease specialist. The exact antibiotics prescribed for this therapy
is at the discretion of the Infectious Disease specialist depending on
the ﬁnal intraoperative culture and sensitivity results. Most cases
involve intravenous vancomycin therapy with or without another
antibiotic agent, most commonly oral rifampin. Our standard
protocol after that is to delay the second stage for another 6 weeks,
and often longer, and to not proceed unless the local physical
ﬁndings are quiescent and the standard laboratory markers
(erythrocyte sedimentation rate (ESR) and C reactive protein (CRP))
are declining towards normal or are already at that point. If there is
any doubt that the infection is controlled, then joint aspiration and
further monitoring are considered. We are prepared to repeat the
wound debridement and reinsert a new antibiotic-loaded articu-
lating spacer if necessary, but these have been required in less than
10% of the overall cases. We do not routinely perform joint aspi-
rations, preferring instead to use the clinical examination and blood
test to guide our decision making. At the second stage, we remove
the PROSTALAC articulated cement spacer and reconstruct the joint
with the appropriate revision implants. We do not elect to perform
a frozen section at the time of the second-stage procedure unless
we encounter a cause for concern. We, however, send routine
intraoperative cultures and continue the intravenous antibiotics
until the ﬁnal intraoperative culture results are available, typically
at 5 days postoperatively. In our study, all 38 patients had negative
intraoperative cultures during the second-stage procedure.9
Infection Prevention and Decolonisation Techniques
Despite our best-known treatment strategy (i.e. two-stage
exchange arthroplasty), the recent literature suggests that we are
still left with a 20e40% failure rate when dealing with methicillin-
resistant periprosthetic infections (Table 1). Thus, we feel that the
focus must include a more concerted effort in the prevention of
these problematic methicillin-resistant organism infections. In
a recent article by Kim et al,14 the authors instituted a screening and
eradication programme for MRSA in patients undergoing elective
orthopaedic surgery at the New England Baptist Hospital in Boston.
The theory behind instituting such a programme was based on the
multiple previous studies, which have shown that S aureus is the
most common causative organism in infections after orthopaedic
operations, and the fact that this organism can be often found in the
nasal passages of patients. The authors wished to investigate
the feasibility and efﬁcacy of instituting a hospital-wide pro-
gramme for identifying carriers and reducing the nasal bacterial
load of these patients before elective orthopaedic operations. They
screened more than 7000 patients for both MRSA and MSSA with
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A.P. Van Houwelingen et al. / Journal of Orthopaedics, Trauma and Rehabilitation 16 (2012) 9e12 11a remarkable screening rate of 95.7%. They identiﬁed 1588 patients
(22.6%) as positive carriers for MSSA and 309 patients (4.4%) as
positive carriers for MRSA. Patients who were screened as carriers
for both types of organisms underwent an eradication protocol
consisting of intranasal mupirocin (Bactroban; GlaxoSmithKline,
Middlesex, UK) and chlorhexidine showers. Their main outcome
measure was the rate of SSI in carriers versus noncarriers as well as
before and after implementing the prescreening programme. They
found that the rate of SSI among MRSA carriers was signiﬁcantly
higher (0.97%) compared with the SSI rate in noncarriers (0.14%).
They also demonstrated more than 50% reduction in the SSI rate
after implementing the screening and eradication protocol
(reduction from 0.45% before the protocol vs. 0.19% once the
screening programme began). The reduction in infection rate was
also relatively greater for MRSA-associated SSI than that for MSSA-
associated infections. This article highlights the importance of
a screening and eradication programme for MRSA carrier status
among patients undergoing elective orthopaedic surgery as it can
lead to statistically signiﬁcant reductions in postoperative rates of
SSI.
At our centre, we are approaching this in a different way. A
comprehensive bacterial decolonisation programme to reduce the
risk of SSI in orthopaedic and other high-risk surgical patients
has just commenced. The decolonisation strategy will combine
two separate elements: (1) chlorhexidine gluconateeimpregnated
wash cloths for skin decolonisation below the neck in the 24 hours
preceding surgery and (2) speciﬁc decolonisation of the anterior
nasal passages, the primary anatomical colonisation site for S
aureus in humans. The nasal decolonisation element proposed in
this quality-improvement project consists of the use of antimicro-
bial photodynamic therapy to rapidly reduce the microbiological
burden in the nares immediately before surgery and uses light
energy to activate a topically applied photoactive agent. It repre-
sents technology that has been in use for some time in dental
patients. It is being evaluated prospectively in a multidisciplinary
surgical setting, with expected results on its effectiveness within 2
years.
Conclusions
Based on the evidence presented, we feel we can make the
following conclusions regarding methicillin-resistant periprosthetic
joint infections:
 Methicillin-resistant periprosthetic joint infections are occur-
ring with increasing frequency, and the failure rates are higher
than that reported in the literature after treatment of nonre-
sistant organisms.
 Single-stage treatment consisting of irrigation, debridement,
and component retention will have a high likelihood of failure
when dealing with a methicillin-resistant organism, and the
treating surgeon should seriously consider performing
a deﬁnitive procedure (i.e. two stage) in the face of a methi-
cillin-resistant periprosthetic infection, unless the infection is
truly acute and debridement can be instituted within a few
days of symptoms. Certainly, if a patient presents with an acute
infection with cementless implants before bone ingrowth, it is
probably preferable to remove the implants rather than
debride the joint.
 Two-stage reconstruction using an antibiotic-impregnated
cement spacer as part of the ﬁrst-stage procedure is our
treatment of choice for periprosthetic infections involving
resistant organisms. However, the treating surgeons must be
aware that the failure rate still ranges from 20% to 40% if
dealing with a methicillin-resistant organism. For that reason,
A.P. Van Houwelingen et al. / Journal of Orthopaedics, Trauma and Rehabilitation 16 (2012) 9e1212new treatment strategies are being explored in collaboration
with infectious disease specialists and basic scientists.
 It is imperative to work to prevent periprosthetic joint infec-
tions by methicillin-resistant organisms. Effective decolonisa-
tion methods have been shown in the literature to decrease the
risk of SSIs, and widespread implementation of such preven-
tion and decolonisation protocols is to be recommended if we
are going to halt the increasing incidence of this difﬁcult
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